Research is not a care plan

Read the whole offer

The Food and Drug Administration (FDA) reviewed sellers’ websites that promoted products for use in people, despite research labels.

In letters checked September 26, 2026, the FDA said these were unapproved drugs and selling them across state lines broke federal law.

Those letters set out the FDA’s claims about particular sellers. They are not court rulings.

Recognise where approval is absent

Compounding means preparing medicine to order.

The FDA medicine-approval records were checked September 26, 2026; no US product had approval for BPC-157 or ipamorelin.

Those records show whether a finished medicine has approval. Making medicine to order has a separate ingredient check, explained next.

Check the named ingredient, too

Under the September 26, 2026 rules, an ordinary pharmacy needs a permitted route for each raw ingredient it uses to make medicine.

The first route is an applicable official drug-quality standard for that ingredient. If there is no applicable standard, that ingredient needs to be in an approved drug.

When neither route applies, the FDA’s extra allowed-ingredients list must include that ingredient.

BPC-157 met none of these tests in the FDA materials checked September 26, 2026. Ordinary pharmacies therefore could not use it as a raw ingredient under these rules.

The library found no permitted ingredient route for ipamorelin acetate either. That is the library’s reading of the records, not a direct FDA decision on every ingredient test.

The FDA still listed safety concerns for ipamorelin acetate in the records checked September 26, 2026.

Ask the pharmacist to show the current written ingredient rule for the exact proposed medicine. A claim that it is simply made to order is not an answer.

Some compounding answers are explicit

The FDA’s statement checked September 26, 2026 says federal law forbids compounding retatrutide or cagrilintide.

Neither has been established as safe and effective for any condition in that FDA statement.

Ask for a care route, not a lab label

Ask who would examine you and who would prescribe, whether the visit is in an office or by video. Ask for their full names and licences, then check them.

A service name is not a person’s name. Ask who answers questions after the visit.